Douglas Adkins

Medicine & Life Sciences

1. Squamous Cell Carcinoma of Head and Neck 100%
2. Cetuximab 63%
3. Head and Neck Neoplasms 53%
4. Survival 37%
5. Squamous Cell Carcinoma 35%
6. Peripheral Blood Stem Cells 32%
7. Stem Cell Transplantation 31%
8. Transplants 31%
9. Neoplasms 30%
10. Bone Marrow Transplantation 27%
11. 130-nm albumin-bound paclitaxel 26%
12. Granulocyte Colony-Stimulating Factor 26%
13. Drug Therapy 26%
14. Sarcoma 25%
15. Graft vs Host Disease 25%
16. Therapeutics 24%
17. Radiotherapy 24%
18. Peripheral Blood Stem Cell Transplantation 23%
19. Cisplatin 23%
20. Autologous Transplantation 23%
21. Induction Chemotherapy 22%
22. Oropharyngeal Neoplasms 22%
23. Progression-Free Survival 21%
24. Whole-Body Irradiation 21%
25. palbociclib 20%
26. Bone Marrow 19%
27. Recurrence 18%
28. Unrelated Donors 18%
29. Docetaxel 18%
30. Tissue Donors 18%
31. pembrolizumab 17%
32. Stem Cells 17%
33. Homologous Transplantation 17%
34. Radiation 16%
35. Neutrophils 16%
36. Transplant Recipients 16%
37. Granulocytes 15%
38. Neck 14%
39. Cyclophosphamide 13%
40. Neoplasm Metastasis 13%
41. Safety 13%
42. dusquetide 12%
43. Breast Neoplasms 12%
44. Bone Neoplasms 12%
45. Albumin-Bound Paclitaxel 12%
46. Platinum 11%
47. temsirolimus 11%
48. Allogeneic Cells 11%
49. Mouth 10%
50. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10%